Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials
Open Access
Abstract
Investigations to understand the function and control of the globin genes have led to some of the most exciting molecular discoveries and biomedical breakthroughs of the 20th and 21st centuries. Extensive characterization of the globin gene locus, accompanied by pioneering work on the utilization of viruses as human gene delivery tools in human hematopoietic stem and progenitor cells (HPSCs), has led to transformative and successful therapies via autologous hematopoietic stem-cell transplant with gene therapy (HSCT-GT). Due to the advanced understanding of the β-globin gene cluster, the first diseases considered for autologous HSCT-GT were two prevalent β-hemoglobinopathies: sickle cell disease and β-thalassemia, both affecting functional β-globin chains and leading to substantial morbidity. Both conditions are suitable for allogeneic HSCT; however, this therapy comes with serious risks and is most effective using an HLA-matched family donor (which is not available for most patients) to obtain optimal therapeutic and safe benefits. Transplants from unrelated or haplo-identical donors carry higher risks, although they are progressively improving. Conversely, HSCT-GT utilizes the patient’s own HSPCs, broadening access to more patients. Several gene therapy clinical trials have been reported to have achieved significant disease improvement, and more are underway. Based on the safety and the therapeutic success of autologous HSCT-GT, the U.S. Food and Drug Administration (FDA) in 2022 approved an HSCT-GT for β-thalassemia (Zynteglo™). This review illuminates the β-globin gene research journey, adversities faced, and achievements reached; it highlights important molecular and genetic findings of the β-globin locus, describes the predominant globin vectors, and concludes by describing promising results from clinical trials for both sickle cell disease and β-thalassemia.Keywords
Funding Information
- UCLA Eli & Edythe Broad Center
This publication has 101 references indexed in Scilit:
- Corepressor-dependent silencing of fetal hemoglobin expression by BCL11AProceedings of the National Academy of Sciences, 2013
- The New Self-Inactivating Lentiviral Vector for Thalassemia Gene Therapy Combining Two HPFH Activating Elements Corrects Human Thalassemic Hematopoietic Stem CellsHuman Gene Therapy, 2012
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010
- Correction of β‐thalassemia major by gene transfer in haematopoietic progenitors of pediatric patientsEMBO Molecular Medicine, 2010
- Transcriptional silencing of γ-globin by BCL11A involves long-range interactions and cooperation with SOX6Genes & Development, 2010
- Correction of Murine Sickle Cell Disease Using γ-Globin Lentiviral Vectors to Mediate High-level Expression of Fetal HemoglobinMolecular Therapy, 2009
- In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of β-thalassemiaProceedings of the National Academy of Sciences, 2008
- An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activationBlood, 2008
- A Positive Role for NLI/Ldb1 in Long-Range β-Globin Locus Control Region FunctionMolecular Cell, 2007
- Lethal β-thalassaemia in mice lacking the erythroid CACCC-transcription factor EKLFNature, 1995